biostudies-literatureUnknown39(12)Fridman MPfizer<h4>Introduction</h4>Alopecia areata (AA), an autoimmune disease, is characterized by non-scarring hair loss involving the scalp, face, and/or body. Prior to 2022, no US Food and Drug Administration (FDA)-approved treatments for AA were available in the USA; existing treatment options had limited efficacy and durability and are often associated with side effects. This study aimed to evaluate the current AA treatment patterns and treatment satisfaction as reported by dermatologists.<h4>Methods</h4>Real-world data from a 2019 cross-sectional survey of US dermatologists and their adult patients with AA were analyzed. Dermatologists provided comprehensive data on their patients with AA, including AA dermatologist-assessed severity, treatments, treatment duration, treatment satisfaction, and reAdvances in therapy5504-5513https://www.ebi.ac.uk/biostudies/studies/S-EPMC9618487biostudies-literatureTreatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States.PMC9618487Ray MShy MEMostaghimi AGandhi KFridman MfalseTreatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States.<h4>Introduction</h4>Alopecia areata (AA), an autoimmune disease, is characterized by non-scarring hair loss involving the scalp, face, and/or body. Prior to 2022, no US Food and Drug Administration (FDA)-approved treatments for AA were available in the USA; existing treatment options had limited efficacy and durability and are often associated with side effects. This study aimed to evaluate the current AA treatment patterns and treatment satisfaction as reported by dermatologists.<h4>Methods</h4>Real-world data from a 2019 cross-sectional survey of US dermatologists and their adult patients with AA were analyzed. Dermatologists provided comprehensive data on their patients with AA, including AA dermatologist-assessed severity, treatments, treatment duration, treatment satisfaction, and re2022-01-01T00:00:00Z2022 Dec2025-04-22T02:08:08.098Z2025-04-05T20:13:13.517ZS-EPMC96184873622302710.1007/s12325-022-02338-4